Moderna, Inc. (MRNA) stock
Close on Nov 12, 2026Market cap $92.36BP/E –Yield –
Moderna, Inc. grew revenue 13.1% to $2.53B over the twelve months to Sep 30, 2026. Free cash flow was -$1.97B. At the latest close the market valued the company at $92.36B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $92.36B
- P/E ratio
- –
- Price to sales
- 36.58
- Price to book
- 13.51
- Dividend yield
- –
- Free cash flow yield
- -2.13%
Fundamentals
- Revenue
- $2.53B
- Net income
- -$2.79B
- EPS, diluted
- -$7.10
- Free cash flow
- -$1.97B
- Book value per share
- $15.90
- Diluted shares
- 430M
Trading
- Next earnings
- Feb 12, 2027 (estimated, before the open)
- Previous close
- $248.69
- Open
- $237.88
- Day's range
- $229.69 – $245.37
- Volume
- 7,021,334
- Average volume (20 days)
- 15,522,394
- Index membership
- S&P 500 (since Sep 2021), Russell 1000, Russell 3000
- Beta (5 years)
- 1.04
- 52-week range
- $22.28 – $280.80
- RSI (14 days)
- 52.4
- Volatility (1 year)
- 194.3%
- Relative volume
- 0.41×
- WACC
- 10.1%
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | MRNA | S&P 500 | Difference | MRNA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +8.2% | -2.7% | +10.9 pts | ||
| 3 months | +263.4% | -1.7% | +265.1 pts | ||
| Year to date | +684.5% | +11.9% | +672.6 pts | ||
| 1 year | +766.2% | +12.0% | +754.2 pts | ||
| 3 years | +230.3% | +78.2% | +152.1 pts | +48.9% | +21.2% |
| 5 years | +0.1% | +73.2% | −73.2 pts | +0.0% | +11.6% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Moderna filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- News
- News
- Results
- Update
About Moderna
Biological Products, (No Diagnostic Substances)
Moderna is a biotechnology company focused on discovering, developing, and manufacturing medicines and vaccines powered by messenger RNA technology. Its commercial product lineup features respiratory immunizations, including Spikevax and mNEXSPIKE for COVID-19, as well as mRESVIA targeting respiratory syncytial virus. The firm organizes its pipeline across infectious diseases, oncology therapeutics, and rare disease treatments, actively evaluating candidates in late-stage clinical trials. Its products serve global populations spanning infants, high-risk individuals, and older adults, reaching patients through retail distribution, clinical healthcare settings, and government collaborations.
Company profile, executives and historyModerna stock: common questions
What is Moderna's stock price?
MRNA closed at $231.35 on Nov 12, 2026, down 6.97% on the day. Over the past 52 weeks it traded between $22.28 and $280.80.
What is Moderna's market cap?
Moderna was worth $92.36B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is MRNA's P/E ratio?
Moderna lost money over the twelve months to Sep 30, 2026 (diluted EPS -$7.10), so it has no meaningful P/E ratio.
How much revenue does Moderna make?
Moderna reported revenue of $2.53B for the twelve months to Sep 30, 2026, up 13.1% from a year earlier.
Does Moderna pay a dividend?
No. Moderna has not paid a cash dividend over the last twelve months.
When does Moderna report earnings next?
Moderna is expected to report Q4 FY2026 results on Feb 12, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has MRNA stock performed over the past year?
Including dividends, MRNA returned +766.2% over the past year, against +12.0% for the S&P 500.
How many MRNA shares are sold short?
33M shares were sold short at the latest FINRA report, 8.81% of the float, or 1.8 days of average trading volume.
Who are Moderna's competitors?
Companies most similar to Moderna by business, industry and size include BNTX, EXEL, BCRX, INSM, NVAX.
See a number that looks wrong?